2.10
0.12 (6.06%)
| Previous Close | 1.98 |
| Open | 1.98 |
| Volume | 50,829 |
| Avg. Volume (3M) | 402,927 |
| Market Cap | 97,206,056 |
| Price / Sales | 2.13 |
| Price / Book | 1.33 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2025 |
| Profit Margin | -246.06% |
| Operating Margin (TTM) | -149.40% |
| Diluted EPS (TTM) | -2.28 |
| Quarterly Revenue Growth (YOY) | 21.00% |
| Total Debt/Equity (MRQ) | 1.37% |
| Current Ratio (MRQ) | 4.89 |
| Operating Cash Flow (TTM) | -54.14 M |
| Levered Free Cash Flow (TTM) | -35.62 M |
| Return on Assets (TTM) | -35.27% |
| Return on Equity (TTM) | -65.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Aadi Bioscience, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | -0.38 |
|
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.10% |
| % Held by Institutions | 50.02% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |